INOVIO Announces Positive Results from REVEAL 1, a Phase 3 Piv...
- Written by LATEST ASIANET NEWS RELEASES
- Published in Asia Net
PLYMOUTH MEETING, Pa., March 2, 2021 /PRNewswire-AsiaNet/ -- -- Trial achieved primary and secondary efficacy endpoints among all evaluable subjects in the Phase 3 multi-center, randomized, double-blind, placebo-controlled trial-- VGX-3100 is the first DNA medicine to achieve efficacy endpoints in a Pha...
Authors: LATEST ASIANET NEWS RELEASES